Trial · NCT05048901
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
NCT05048901, Phase 1, Phase 2, Recruiting, National Health Research Institutes, Taiwan
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors. Trials, record NCT05048901. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05048901
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
- NCT number
- NCT05048901
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 49 participants, estimated
- Lead sponsor
- National Health Research Institutes, Taiwan
- Conditions
- Neuroendocrine Tumors,Gastroenteropancreatic
- Interventions
- Cabozantinib, Lanreotide
- First posted
- 2021-09-17
- Last updated
- 2026-04-09
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | to determine the maximal tolerated dose of cabozantinib | Phase I last patient in has been treated for 28 days | The dose of maximal tolerated dose of carbozantinib combination of cabozantinib and lanreotide for the recommended dose in phase II study. |
| Primary | Progression free survival | The time from registration to occurrence of progression based on the tumor response assessment by scheduled or un- scheduled CT scan or MRI. (whichever occurs first assessed up to 72 months) | The date of first study treatment to the date of disease progression. |
| Secondary | Response rate | Every 8 weeks for first 4 cycles then every 3 cycles (12 weeks) until disease progress. (each cycle is 28 days) | Estimates of response category frequencies with 95% confidence intervals will be computed. |
| Secondary | Overall survival | The time from registration to death from any cause assessed up to 72 months. | the time from the date of first study treatment to the date of patient death, due to any cause, or to the last date the patient was known to be alive. |
| Secondary | Toxicities | Approximately 72 months. | Treatment toxicities and safety profiles,assessed by CTCAE v5.0 |
| Secondary | Genetic study | Approximately 72 months. | Genetic study assessed by Next Generation Sequencing |
| Secondary | Somatic mutation | Approximately 72 months. | Somatic mutation assessed by Next Generation Sequencing |
| Secondary | circulating tumor cells | Approximately 72 months. | circulating tumor cells assessed by flow cytometry. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42976416 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05048901
GET https://conductscience.org/api/trials/v1/NCT05048901/registered